Neurodevelopmental scores were lower across every domain in children with sickle cell disease

Children under five years with sickle cell disease in eastern Uganda showed consistently poorer neurodevelopment than their peers without the disorder, with differences emerging across social, gross motor, fine motor, and language domains. In a cross-sectional study at Mbale Regional Referral Hospital, investigators assessed 350 children under five years between March and September 2025, including 117 children with sickle cell disease and 233 community controls. The neurodevelopment gap was not subtle. Children with sickle cell disease had 0.89 lower developmental age z-scores than children without the condition, a finding that points to early vulnerability during a period when brain growth, motor acquisition, and language development are moving rapidly in parallel.

The study used the Malawi Development Assessment Tool, a practical instrument for evaluating developmental performance in young children in low-resource settings. Median age in the cohort was 40.9 months, with an interquartile range of 27.8 to 54.3 months. At that age, delays in language and social interaction can spill into school readiness, caregiver burden, and later educational performance. The signal here is clinically important because it suggests neurodevelopmental disadvantage is already established before age five, not merely emerging in later childhood after repeated vaso-occlusive injury becomes more obvious.

One sentence in the dataset carries particular bedside weight: children with sickle cell disease who were not enrolled on hydroxyurea had lower social and language scores than those receiving the drug.

Among children with sickle cell disease, lack of hydroxyurea exposure was associated with a 0.4-point reduction in social and language domains compared with those on hydroxyurea. The average exposure effect from inverse probability of treatment weighting was -0.87, with a 95% confidence interval from -1.19 to -0.55. The average exposure effect among the exposed was -0.62, with a 95% confidence interval from -1.01 to -0.23. These estimates strengthen the impression that sickle cell disease itself, rather than simple background variation, is tied to developmental disadvantage in early childhood. Weighting methods cannot replace randomization, but they do help balance measured differences between groups and make the association more credible in a real-world pediatric clinic population.

Why sickle cell disease can affect early brain development

The biology is plausible. Chronic hemolysis, episodic vaso-occlusion, anemia, and inflammation can all interfere with oxygen delivery to the developing brain. In a child whose nervous system is still wiring language networks, motor planning, and social responsiveness, repeated reductions in oxygenation and microvascular flow may alter developmental trajectories long before overt neurologic injury is diagnosed. Silent cerebral infarction and other subclinical neurologic insults are well recognized in sickle cell disease, and even without a clinically obvious stroke, cumulative vascular stress may degrade the developmental reserve needed for normal acquisition of milestones. That mechanism fits the pattern seen here: broad developmental impairment rather than a single isolated deficit.

Hydroxyurea is relevant because it can raise fetal hemoglobin, reduce hemolysis, and lessen the frequency of painful or ischemic complications. Those effects offer a biologically credible explanation for the better social and language scores observed in treated children. The data do not prove hydroxyurea directly improves neurodevelopment, but they do suggest that disease modification may extend beyond crisis reduction and into the domain of early neurodevelopmental preservation. In settings where access, adherence, and follow-up remain uneven, that possibility should influence how clinicians discuss long-term treatment goals with families.

Developmental screening belongs inside routine sickle cell care

The practical implication is straightforward: neurodevelopment should not be treated as a separate concern from hematologic care. Children with sickle cell disease attend clinics repeatedly for transfusion, infection prevention, symptom management, and growth surveillance. Those visits create a built-in opportunity to screen for language delay, social impairment, and motor concerns before the gap widens. Routine integration of developmental assessment into sickle cell clinics could help clinicians identify children who need referral, targeted stimulation, hearing evaluation, speech-language support, or closer follow-up.

The study also reinforces the value of community comparison groups. By measuring children with and without sickle cell disease in the same regional setting, the analysis avoids the trap of assuming that all developmental delay in a low-resource environment is explained by social adversity alone. Children without sickle cell disease served as the benchmark, and the developmental deficit remained pronounced after weighting adjustments. The result points to disease-specific risk layered on top of the broader challenges facing child health services in eastern Uganda.

No single developmental tool can capture the entire neurologic burden of sickle cell disease, and cross-sectional data cannot determine when the developmental gap first appeared. Yet the pattern is hard to dismiss. Across the measured domains, children with sickle cell disease performed worse, and those not receiving hydroxyurea did worse still in social and language measures. For pediatric teams, that combination argues for earlier neurodevelopmental surveillance, stronger counseling around hydroxyurea, and more deliberate linkage between hematology services and child development support.

The findings leave one pressing clinical question open: how much of the observed developmental disadvantage can be prevented if sickle cell disease is diagnosed earlier and treated more consistently in infancy and toddlerhood?


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by PLOS Medicine.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA